2026-W23

# Weekly Position Deep-Dive — W3
**ISO Week:** 2026-W23 (Mon 2026-06-01 → Sun 2026-06-07) | **Research as of:** Sun 2026-05-31 (after the W22 market week; next session Mon 2026-06-01 cash open)
**Scope:** Strategy B open positions — **HCA, ZBRA, BRC, TJX, AZO, BURL**. Strategies A / C / E flat (zero open positions). Strategy D excluded per W3 spec (RTX and DIS covered in M4).
**Rev-35 framing (2026-05-30):** Strategy.md rev 35 (owner directive 5/30) removed ALL holdings-**count** caps across A/B/C/D — including B's 3-per-GICS-sector cap. Concurrent-position correlation is monitored only (KL #12 metric (d)), never capped. Retained: 2%-per-position size cap, D's 30%-of-NAV sector *exposure* cap, kill triggers. The book below carries TJX/AZO/BURL = three concurrent Consumer Discretionary positions; this is no longer a cap concern, only a KL #12 correlation monitoring concern at the next scheduled review (Wed 2026-06-03 event `k9vtudr7d40ukto3vfhutcdbls`).
**Sources:** Portfolio_Ledger.md (fills + invalidation criteria); Decision_Log.md (live, thesis pointers; 2026-05-26 → 2026-05-30 entries); Strategy.md (B exit rules); Operating_Protocols.md (§3, §8, §10 incl. rev-35 update); Regime_State.md. Tavily web research 2026-05-31: stockanalysis.com (OHLC primary sources for HCA / ZBRA / BRC / AZO; TJX investor IR for TJX OHLC); Yahoo Finance; CNBC; Trefis; TIKR; Barchart; Quiver; StockTitan; MarketWatch; MarketBeat; Motley Fool (BURL Q1 transcript); Brady 8-K + Honeywell IR (PSS deal status); Zacks (AZO Q3 readthrough).

> **Data-integrity notes:**
> 1. **BURL is PROVISIONAL.** Fill inferred ≈ $300.60 / ≈ 0.1255 shares (open below the $303 DAY limit). No IBKR screenshot has been reconciled and no Decision_Log GO entry exists for BURL. The convergence target $313.71 has been **exceeded** at the 5/29 close $323.83. Convergence exit is DUE but is the canonical responsibility of the fill-capture session (event `re0irs9o1rcrg0c98rh9ranih0`, 2026-05-29 14:30 MT, past-fire / unreconciled per Decision_Log 2026-05-30 D3 Flag 1). W3 surfaces this as IMMEDIATE-ACTION but does NOT stage exits — staging is owed to the screenshot-driven fill-capture session.
> 2. **HCA** mark trajectory (5/22 $394.07 → 5/29 $378.54) sits well below the W3 prior cycle's $396.67 reference. Position is now **−12.61%** vs cost basis incl. comm with **27 days to time-exit** and convergence $442.85 = **+17.0%** above spot — wider than at entry. Time-expiry watch elevated.
> 3. **AZO** has drifted lower **every session** since entry (5/27 $3,027.48 → 5/29 $2,935.19 = 52-week low). Two material post-print PT cuts on 5/28 (Citigroup Buy $4,300 → $3,700; Jefferies → $4,000). Cumulative 4-session adverse mark −5.64% vs $3,110.69 fill; sub-pattern 4 (international-to-domestic-contagion) watch is **HEIGHTENED but not tripped** — no FY26 domestic-SSS guide cut and the PT cluster remains well above spot.

---

## IMMEDIATE-ACTION: **BURL convergence exit is DUE** (fill-capture session owns staging)

BURL closed Fri 5/29 at **$323.83**, above the immutable convergence target **$313.71**, the day of fill. Per Strategy.md B exit rules ("convergence target reached"), the position is **convergence-exit-due**. Why W3 does **not** stage an exit order here:

- BURL fill is **PROVISIONAL** (Portfolio_Ledger 2026-05-29 + Decision_Log 2026-05-29 BKE entry + 2026-05-30 D3 Flag 1). Exact fill price, share count, and commission are pending the IBKR Positions + Trades screenshot. Staging a SELL of an unverified share count would either (a) be wrong by float-share decimals (the staged 2% sizing produced ~$37.7 principal, ~0.1255 shares at inferred $300.60, but the real number could differ by a digit), or (b) cancel-and-replace once the screenshot lands. Either is worse than letting the fill-capture session stage the convergence exit on the verified figures.
- The fill-capture session is the canonical reconciliation path established at staging (event `re0irs9o1rcrg0c98rh9ranih0`) and re-affirmed in Decision_Log 2026-05-29 BKE + 2026-05-30 D3.
- The time-based-exit backstop (`91sgtm5com859vib9gu1a0brfs`, 2026-07-28) is live, so the position is not unprotected if convergence-exit staging slips by a session.

**What W4 should do:** Do NOT stage a BURL exit. Surface this flag in chat output so the operator pastes the IBKR screenshot into the fill-capture session prompt (the Decision_Log 2026-05-30 D3 entry already contains the action list for that session: (a) confirm exact fill/qty/commission, (b) write the missing Decision_Log GO thesis entry, (c) finalize Portfolio_Ledger BURL OPEN section, (d) **stage the convergence-exit SELL — fastest path is a market sell at the Mon 6/1 open given price is already through target**, (e) create the convergence-exit execute-order + fill-capture calendar events). All other W4 actions (HCA / ZBRA / BRC / TJX / AZO) are HOLD.

No other position has a tripped invalidation criterion. Adverse marks on HCA (−12.6%) and AZO (−5.6%) are **not** exit triggers — Strategy.md gives B longs no price stop (rev 13 stop-loss applies only to shorts; this book is all long).

---

## Strategies A, C, E — No Open Positions

- **Strategy A:** Zero open. Router state DO-NOT-ACTIVATE per Regime_State.md; M1 6/1 will re-test. Nothing to deep-dive.
- **Strategy C:** Zero open structures. Next FOMC 2026-06-16/17 (HYBRID router gate). Thesis-construction event already scheduled Mon 2026-06-08 09:00 MT (`7pbkg1kh2pge7midfiqnj6edvk`).
- **Strategy E:** Zero open pair positions. Router state DO-NOT-ACTIVATE per 2026-04-25 divergence review. Nothing to deep-dive.

---

## Strategy B — Open Position Deep-Dives

**Router state:** B router **ACTIVATE** (SPY Trend ≠ DOWN; VIX ≠ HIGH). No W22 event flipped either clause (Fri 5/29 three-way fresh-record close per Daily.md 5/30: SPX 7,580 / Nasdaq 26,972 / Dow 51,032 first 51k close; VIX 15.32 multi-week low = NORMAL retained; M1 6/1 owns formal re-call).

**B book — last-confirmed marks (primary-source closes Fri 2026-05-29):**

| Position | Status | Fill date | Fill px | Cost basis (incl. comm) | Convergence target | 5/29 close | Δ vs cost | Δ to target | Time-based exit | Days to time-exit |
|----------|--------|-----------|---------|--------------------------|--------------------|-----------|-----------|-------------|-----------------|--------------------|
| HCA  | OPEN | 2026-04-28 | $433.46 | $28.11 | $442.85 | **$378.54** | **−12.61%** | +17.0% | 2026-06-27 | **27** |
| ZBRA | OPEN | 2026-05-14 | $249.52 | $37.90 | $264.00 | **$243.63** | −3.24% | +8.36% | 2026-07-13 | 43 |
| BRC  | OPEN | 2026-05-22 | $84.97  | $37.86 | $88.80  | **$86.00** ¹ | +0.06% ² | +3.26% | 2026-07-21 | 51 |
| TJX  | OPEN | 2026-05-26 | $158.50 | $37.53 | $164.50 | **$154.75** | −2.37% | +6.30% | 2026-07-24 | 54 |
| AZO  | OPEN | 2026-05-27 | $3,110.69 | $37.99 | $3,200 | **$2,935.19** | **−5.64%** | +9.02% | 2026-07-24 | 54 |
| BURL | OPEN (PROV.) | 2026-05-29 | ≈ $300.60 | ≈ $37.85 ³ | $313.71 | **$323.83** | **+7.50%** | **target exceeded** | 2026-07-28 | 58 |

¹ BRC 5/29 close not directly in collected primary sources — best estimate $86.00 ± $0.50 from MarketWatch intraday $86.29 (mid-day Fri) and inferred from stockanalysis prior-close $86.11. **D2 to verify Fri 5/29 close via primary source at next session.**
² Mark vs cost basis incl. commission; BRC is essentially flat (cost basis $37.86; 0.4415 shares × ~$86 = $37.97).
³ BURL principal/qty PROVISIONAL — inferred from staged ~$37.7 principal at open price $300.60. Pending IBKR screenshot reconciliation. Cost basis estimate assumes $0.35 commission.

**Cross-cuts:** Six concurrent B longs spanning Health Care Facilities (HCA), Communications Equipment (ZBRA), Industrial Machinery (BRC), Apparel Retail (TJX, BURL), Automotive Retail (AZO). Two Consumer-Disc apparel longs (TJX + BURL) plus an AZO Consumer-Disc Automotive Retail long. KL #12 metric (d) first computation Wed 2026-06-03 — the apparel pair (TJX × BURL) is the most likely correlation flag.

---

### B-1: HCA Healthcare (OPEN — drawdown deepening; time-expiry watch elevated)

**1. Current thesis status.** Post-event mispricing long entered 2026-04-28 at $433.46; convergence $442.85 (25% gap-fill, MEDIUM-LOW ~45-50% conviction per Operating_Protocols §8). Thesis: the Apr 24 Q1-print reaction (−8.77% to $432.46) overshot relative to volume softness that management framed as transient (mild flu season + Winter Storm Fern + Medicaid supplemental-payment timing). FY26 guide reaffirmed ($76.5–80.0B revenue / $15.55–16.45B adj EBITDA / $29.10–31.50 EPS). Stockanalysis.com primary source for week-21/22 close trajectory: 5/22 $394.07 → 5/26 $392.42 → 5/27 $392.15 → 5/28 $384.39 → **5/29 $378.54**. Trefis logged a 5-day cumulative loss of −9.3% through the prior week; market cap fell to ~$88B. **Mark sits −12.61% vs cost basis** with 27 calendar days to the 2026-06-27 time-stop.

**2. Competitive landscape.** Hospital-peer tape soft in sympathy through the week (UHS / THC moves not in collected source set; W3 prior cycle's −1.67% / −0.55% comparators stand as the most recent calibration). No peer 8-K, pre-announcement, or guidance change re-priced the group this week. No fresh THC / UHS print between Apr-end and now (criterion-(iii)/(iv) checkpoints already passed at staging).

**3. Fundamental developments.** **One HCA-specific corporate action this week:** 2026-05-27 press release — HCA Healthcare announces agreement to acquire **The College of Health Care Professions (CHCP)** (allied-health-training school; terms not disclosed; subject to regulatory approval). This is a **non-criterion** tuck-in (workforce-development vertical-integration; no FY26 EPS framework impact disclosed); does not bear on criteria (i)/(ii). No HCA 8-K reducing guide; no pre-announcement; no analyst-action wave directly identified in the primary-source pull (TD Cowen's Apr-27 PT trim $561→$500 with Buy maintained remains the standing reset). The Trefis piece characterizes operating performance as "Weak" + financial condition as "Risky" — sentiment readthrough, not a new disclosure.

**4. Sector / macro context.** The structural overhang remains federal **Medicaid policy**, but the relevant policy package — the FY 2026 budget-reconciliation bill (the "Big Beautiful Bill," H.R. 1) — was **already passed and signed in July 2025** with ~$911B / 10-yr federal Medicaid cuts (KFF / Fierce / AMA references; this is well-known macro). The "most immediate effects" (state provider-tax freezes; new-tax/-increase prohibitions) are working through state budgets in 2026 with the deepest cuts scheduled October 2027+ (KFF). **No new federally-enacted change this week** alters a criterion (i) threshold. The market is repricing the slow-drip risk into the hospital tape rather than reacting to a specific new event — i.e., the drawdown is sentiment/macro overhang on already-priced policy, not a fresh information shock.

**5. Thesis-invalidation signals.** Per ledger entry-record:
- (i) FY26 guide cut below floors ($76.5B revenue / $15.55B adj EBITDA / $29.10 EPS) — **NOT-TRIPPED.**
- (ii) HCA pre-announcement / negative business update — **NOT-TRIPPED.**
- (iii) THC Apr-30 print establishing sector-wide shortfall — **NOT-TRIPPED** (resolved at staging).
- (iv) UHS Apr-27 corroboration — **CLEARED.**
No new invalidation evidence. The cumulative deepening drawdown is sentiment-driven, not criterion-triggered.

**6. Time to thesis resolution.** **27 calendar days to time-exit 2026-06-27.** Convergence $442.85 sits **+17.0%** above the 5/29 close — substantially wider than at entry. The probability of convergence within the remaining window is materially lower than at staging absent a sharp policy/sentiment reversal. **HCA most likely closes on time-expiry** (the structurally-expected lower-conviction tail flagged at MEDIUM-LOW staging). Mid-window pulse-check event NOT scheduled (none was created at staging); time-exit event live (`u9l9544ighc4d9o1l44u7pr0uc`, Fri 2026-06-26 09:25 MT).

**Recommendation: HOLD — time-expiry watch ELEVATED.** No invalidation criterion tripped; adverse mark carries no exit trigger for a B long. Catalyst paths for early resolution: (a) HCA-specific guide reaffirmation at any sell-side conference / 8-K disclosure in the remaining 27 days (would lift mark toward target); (b) federal Medicaid headline that crystallizes into a criterion-(i) HCA 8-K (would invalidate); (c) M1 6/1 fundamental DNA re-derivation possibly shifting B router state (would not change exit but would affect new-entry posture). **Cited rule on close:** if time-stop fires 6/27 with no convergence and no invalidation, exit per Strategy.md "Timeline expiry at 60 days." No W4 action required this cycle — the 6/26 time-exit event handles staging at expiry.

---

### B-2: Zebra Technologies (OPEN — mid-path; thesis intact)

**1. Current thesis status.** Post-event mispricing long entered 2026-05-14 at $249.52; convergence $264.00 (25% gap-fill, MEDIUM conviction). Thesis: Q1-print (Tue 5/12 BMO, Day-0 C/C +11.4%) under-rated a clean beat-and-raise (net sales $1.50B, +14.3% YoY; non-GAAP EPS $4.75 vs $4.27 consensus, +11.9% beat; FY26 guide raised to 10–14% sales growth). Stockanalysis.com / Yahoo OHLC for the week: 5/22 $255.55 → 5/26 $252.16 → … → **5/29 $243.63 (AH $245.00 +0.56%)**. Mark drifted −4.74% off the 5/22 high; mark vs cost basis incl. comm **−3.24%** ($37.90 → $36.67).

**2. Competitive landscape.** AIDC/Comm-Equipment peers (Motorola Solutions, Ciena, Lumentum) mixed and not driven by any AIDC-group event week 22. The week's notable ZBRA-adjacent item is shareholder-meeting governance: 2026-05-19 ZBRA shareholders approved the 2026 Incentive Plan, elected four Class III directors, and ratified EY auditor — non-criterion governance ratifications (The Globe and Mail / TipRanks). The Skild AI acquisition of Zebra's Robotics Automation business (Symmetry Fulfillment) — flagged in the prior W3 — remains a non-material divestiture.

**3. Fundamental developments.** Q1 print stands: FY26 sales growth **raised to 10–14%** (≈7pts inorganic/FX), Q2 sales-growth guide 14–17%, FY26 adj EBITDA margin ~22%, FY26 non-GAAP EPS $18.30–18.70, FCF > $900M. Simply Wall St narrative carries forward — the raised guide is the durable post-print bull marker. No fresh 8-K or pre-announcement this week. Spark / TipRanks AI summary continues to rate ZBRA "Outperform" with technical signal noted as still below 200-DMA (sentiment-momentum overhang, not a criterion event).

**4. Sector / macro context.** Industrial-automation / warehouse-AIDC end markets sit inside the W22 risk-on tape (May Nasdaq +8%, "best month since 2001" per IBD; computer hardware/peripherals group +69% May per Daily.md 5/30). Tariff-overlay drag mentioned but mitigated per ZBRA Q1 commentary. No sector-wide negative catalyst week 22.

**5. Thesis-invalidation signals.** Per ledger entry-record:
- (i) FY26 framework reset (EPS guide < $18.30 mid / sales-guide retraction / adj-OM < 24.5%) — **NOT-TRIPPED** (guide was raised).
- (ii) Demand / customer-weakness pre-announcement — **NOT-TRIPPED.**
- (iii) Tariff-regime ZBRA-specific adverse disclosure — **NOT-TRIPPED.**
- (iv) Sub-pattern-1 cluster escalation (≥3 post-fill aggressive +10%+ PT raises re-rating the stock to information-priced equilibrium) — **NOT-TRIPPED.** Post-print PT activity remains the mixed split documented at staging (KeyBanc OW $305; BNP $370; Barclays $345; Needham $345; Baird $310 vs Citi Neutral $284 / Truist Hold $267); the Globe-and-Mail notes a "Buy with $345 PT" as the most recent analyst rating context — not a ≥3-firm aggressive +10% wave.

**6. Time to thesis resolution.** **43 calendar days to time-exit 2026-07-13.** Convergence +8.4% above spot — achievable within the window. **Mid-window pulse-check live: Tue 2026-06-09 15:30 MT (event `6p9eotfrdd0eae2pvoccrbj95o`).** Time-exit event live (`b2gka8hncerbnfh6m9j2hq4k2g`, Mon 2026-07-13 07:15 MT).

**Recommendation: HOLD.** No criterion tripped; thesis intact. Sub-pattern-1 watch armed; mid-window pulse-check Tue 6/9 owns the structured re-look.

---

### B-3: Brady Corporation (OPEN — bounced off convergence intraday Tue, faded back; thesis intact)

**1. Current thesis status.** Post-event mispricing long entered Fri 2026-05-22 at $84.97; convergence $88.80 (25% gap-fill, MEDIUM-LOW ~45-50% conviction; overturned a Calendar-MCP-outage procedural NO-GO). Thesis: fiscal Q3 print (Mon 5/18 BMO) held a ~17% undershoot to a ~$101.50 PT cluster on thin coverage. Week 22 OHLC: 5/22 $87.52 → **5/26 high $89.05 (intraday >$88.80 target) but close $87.78** (stockanalysis) → 5/27 $86.96 → 5/28 ~$86.11 → 5/29 ~$86 (MarketWatch mid-day $86.29). **BRC printed above the $88.80 convergence target intraday Tue 5/26 but never closed above it** — Strategy.md "Convergence target reached" is canonically applied at **close**, not intraday, in our own precedent (META 5/27 first close above $626.21 triggered exit; IBM closed $252.97/254.36 above $245 before exit was staged). Position is effectively flat vs cost basis ($37.86 cost vs $37.97 mark at $86.00).

**2. Competitive landscape.** Identification / safety-products peers (Avery Dennison, CCL, Panduit, 3M) unmoved relative to BRC this week. The structural item — **Honeywell PSS acquisition** ($1.4B cash, 8× EBITDA, announced 2026-04-20; expected close H2 calendar 2026 subject to regulatory approvals) — is confirmed on track. Honeywell investor IR + Brady 8-K both reaffirm the H2-2026 close, and the deal is framed as accelerating Honeywell's portfolio-simplification ahead of the Q3 2026 Aerospace spin (Honeywell still actively assessing strategic alternatives for the separate Warehouse and Workflow Solutions / Intelligrated / Transnorm business — no read-through to BRC PSS deal). No regulatory friction signal this week.

**3. Fundamental developments.** Q3 print remains the active catalyst: fiscal Q3 sales $435.24M (+13.8% YoY); diluted EPS $1.21 (vs $1.09 PY); adj EPS $1.50 (+23%); 8.2% organic growth; Wire Identification +19% on data-center demand; **FY26 adj EPS guide raised to $5.20–$5.30** (from $4.95–$5.15); GAAP FY26 guide $4.66–$4.76. Q3-after PT actions narrow: MarketBeat tracks "Wall Street Loves BRC" with current consensus PT ~$101.50; coverage remains structurally thin (Sidoti-class boutique + a few mid-tier shops). No multi-firm aggressive PT-raise wave to information-price the stock to ~$100-102.

**4. Sector / macro context.** Industrial-identification / workplace-safety / data-center labeling demand is buoyed by the May AI-infrastructure / data-center capex narrative (Daily.md 5/30: BRC is among the names tagged to data-center secular tailwinds). No macro catalyst specifically adverse to BRC's MRO/OEM exposure week 22.

**5. Thesis-invalidation signals.** Per ledger entry-record:
- (i) FY26 adj-EPS guide below the new $5.20 floor — **NOT-TRIPPED.**
- (ii) Honeywell-PSS deal termination or negative business / demand update — **NOT-TRIPPED** (deal on track per 8-K + Honeywell IR; no FTC/HSR adverse signal in collected sources).
- (iii) Sub-pattern-1 escalation (≥3-firm aggressive PT-raise wave re-rating to ~$100-102) — **NOT-TRIPPED** (thin coverage; no wave).
None tripped.

**6. Time to thesis resolution.** **51 calendar days to time-exit 2026-07-21.** With only **+3.3% to target** and an intraday print above target already on the books, the probability of convergence-exit firing within the next 1–2 weeks is high absent reversal. Time-exit event live (`sli3tl3msrhsuq731apqg7s9io`, Tue 2026-07-21 07:15 MT). BRC fiscal Q4 print falls inside the window (fiscal year ends 2026-07-31; Q4 print historically ~Sep), so unlikely to be in window unless accelerated — confirmed: no Q4 print risk inside the 60-day exit window.

**Recommendation: HOLD — APPROACHING TARGET.** No criterion tripped. **D2 daily-open watch:** if BRC closes ≥ $88.80 on any session in the holding window, stage the convergence SELL immediately per Strategy.md (parallel to META 5/27 first-close-above precedent). The 5/26 intraday $89.05 print is informational (not an exit trigger), but it confirms the convergence path is live.

---

### B-4: TJX Companies (OPEN — entered Tue 5/26; modest adverse drift; thesis intact)

**1. Current thesis status.** Post-event mispricing long entered 2026-05-26 at $158.50 (Limit BUY 0.2346 GTC, operator-discretion tighter limit + GTC vs staged $162 Day Wed; META/HCA/ZBRA tighter-limit-at-execution pattern); convergence $164.50 (25% gap-fill, MEDIUM-LOW ~45-50% conviction). Thesis: Q1 FY27 print (Wed 5/20 BMO) under-rated a clean beat-and-raise — net sales $14.32B (+9% YoY), comps +6% ("well above plan"), diluted EPS $1.19 (+29% YoY), pretax margin +170bps, FY27 guide raised across all metrics. TJX investor-IR primary-source OHLC for entry-week: 5/26 $158.97 / 5/27 $157.01 / 5/28 $154.89 / **5/29 $154.75** (Yahoo confirms 5/29 close $154.75, AH unchanged). Mark vs cost basis incl. comm: −2.37% (within Day-4 fill noise).

**2. Competitive landscape.** **Off-price peer print cross-corroborates the thesis:** Ross Stores (ROST) Q1 results also beat / well-reviewed (Morningstar PT raise to $258; ROST trades $217.52). Cross-section: TJX+/ROST+ on similar comp pictures (the trade-down / off-price-channel-strength tape); BURL Q1 print 5/29 also beat-and-raise (FY26 EPS guide raised; Day-1 +7.76%) — same off-price tailwind. WMT / TGT did not introduce a structural off-price-channel-launch event this week. No competitive-disruption signal.

**3. Fundamental developments.** Print stands; analyst-action cluster post-print: **UBS Buy $193 → $197 (+2.1%) 5/21; Truist $175 → $190 (+8.6%); Telsey $175 → $185 (+5.7%); Evercore ISI $171 → $175 (+2.3%)**. Median Street target ~$177.63 (stockanalysis); consensus rating Strong Buy across 21 analysts. Max raise +8.6% (Truist) — **well below the ≥20% multi-firm aggressive-re-rating threshold for sub-pattern-1 escalation.** Yahoo Scout sentiment summary aligns: "Wall Street Loves TJX, But Is the Stock Still a Good Deal" framing — narrative-rich but no information-pricing wave.

**4. Sector / macro context.** Apparel-retail / off-price subset benefits from the Yardeni "G-shaped consumer divergence" framing carried in Barron's into the weekend (Daily.md 5/30) — top-end consumers strong, middle-and-low under pressure → off-price share gains. This is supportive of the thesis. AEO Q1 (5/28) and BKE Q1 (5/29) both fell on specialty-apparel-cohort weakness — **not a TJX/BURL off-price drag** (Decision_Log 2026-05-30 substantive re-evaluation explicitly distinguishes specialty-apparel weakness from off-price strength; cohort base-rate is favorable for TJX).

**5. Thesis-invalidation signals.** Per ledger entry-record:
- (i) TJX 8-K materially cutting FY27 comp guidance below 2-3% floor / pretax margin below 11.7% floor — **NOT-TRIPPED.**
- (ii) Structural change in off-price competitive positioning (WMT/TGT formal aggressive off-price channel launch adverse to TJX) — **NOT-TRIPPED.**
- (iii) Sub-pattern-1 escalation (≥3-firm aggressive PT-raise wave ≥20% re-rating to ~$185-190 information-priced equilibrium) — **NOT-TRIPPED** (max raise Truist +8.6% well below threshold).
None tripped.

**6. Time to thesis resolution.** **54 calendar days to time-exit 2026-07-24.** Convergence +6.3% above 5/29 close — achievable within window; thesis-resolution texture similar to META (entered −2% below convergence, resolved in 23 days on a thesis-aligned narrative event). Time-exit event live (`0g1smg50pf89jo3or6ompaht4o`, Fri 2026-07-24 07:15 MT). Q2 FY27 print expected ~mid-August (outside window — confirms no print-in-window catalyst risk).

**Recommendation: HOLD.** No criterion tripped; sub-pattern-1 clears decisively; off-price-tailwind cross-section corroborates; modest adverse drift is within Day-4 noise. KL #12 6/3 review will compute TJX × BURL pairwise correlation — likely the highest pair in the book given same sub-industry; flag if average pair correlation > 0.5 (monitoring, not capping).

---

### B-5: AutoZone (OPEN — heightened watch; PT-cuts post-print + continuing adverse drift; criteria NOT-TRIPPED)

**1. Current thesis status.** Post-event mispricing long entered Wed 2026-05-27 at $3,110.69 (Limit BUY 0.0121 Day; entry timing intentional — Day-0 was 5/26 BMO print + −9% reaction to 52-week-low context). Convergence $3,200 (25% gap-fill from ~$3,100.11 Day-0 reference toward ~$3,500 PT-median; MEDIUM-LOW conviction). Thesis: market overreacted to a ~0.4% revenue miss while domestic SSS accelerated to +4.1% constant-currency / +5.5% reported (strongest in 3+ years), domestic commercial +10.4%, total sales +8.4% (largest YoY growth in 3+ years), 82 net new stores. Stockanalysis.com primary-source close trajectory: 5/26 $3,100.11 (−8.99%) → 5/27 $3,027.48 (−2.34%) → 5/28 $3,007.08 (−0.67%) → **5/29 $2,935.19 (−2.39%; 52-week LOW)**. **Mark vs cost basis incl. comm: −5.64%** ($37.99 → $35.52).

**2. Competitive landscape.** Direct peers: O'Reilly (ORLY) trades at materially higher multiples (19.09× NTM EV/EBITDA / 26.93× P/E per TIKR) vs AZO compressed to 13.15× NTM EV/EBITDA / 18.46× P/E — the multiple gap widened post-print. ORLY's relative-positioning has not been re-rated downward by the AZO print (no ORLY guide-cut / no cross-section AAP read-through in collected sources). GPC −0.56% and AAP +0.63% sympathy moves on AZO Q3 day are modest, supporting the AZO-idiosyncratic-reaction framing.

**3. Fundamental developments — material PT cuts post-print are the dominant new development this week:**
- **Citigroup (5/28):** **Maintains Buy; PT $4,300 → $3,700 (−14.0%)** — Yahoo confirmed.
- **Jefferies (5/28):** PT lowered to **$4,000** (cut from prior; MarketBeat).
- **Morningstar (5/26):** AZO "Earnings: Commercial Momentum Persists, but Margin Pressure Lingers; Shares Fairly Valued" — moves to "Fairly Valued" framing post-print (not a cut to neutral, but tone shift).
- Other firms — DLTR raised by Morningstar 5/27, ROST raised — peers raised, AZO trimmed.
- TIKR (5/27) characterizes the Street as "not revised targets downward" with mean PT $4,204.74 / +36% upside / "16 Buys / 5 Outperforms / 4 Holds / 1 No Opinion / 1 Underperform / 1 Sell" — but Citi (5/28) is the post-TIKR data point that begins the cut wave; the dynamic is in motion through the weekend.

**This is the live criterion-(iii) sub-pattern 4 watch — see Section 5.** Note: even after the Citi and Jefferies cuts, $3,700 / $4,000 PTs remain **~+26% / +36%** above the 5/29 close $2,935.19 — i.e., the **PT cluster is NOT being re-rated toward spot (no information-driven repricing yet)**, distinct from the AEO 5/29 sub-pattern 4a precedent where 4 firms cut PTs to at-or-below spot the same day (Decision_Log 2026-05-30 AEO substantive NO-GO).

**4. Sector / macro context.** Consumer Discretionary tape mixed: Yardeni "G-shaped consumer divergence" framing (Barron's) is **net negative for AZO Mexico/Brazil exposure** (Mexico domestic SSS +1.6% constant-currency on Q3; Q3 transcript flags "slower economic growth in the country") but **net neutral-to-positive for US domestic** (DIY +2.2%; DIFM +10.4%; commercial-momentum continues). Q3 transcript: tariff-overlay drag mentioned + LIFO charge $20M Q3 + $30M planned Q4 (forecast FY26 LIFO total $207M vs FY25 $64M — material headwind). Late-quarter softness attributed by management to "weather-related noise" — sentiment-vs-information classification stays open.

**5. Thesis-invalidation signals.** Per ledger entry-record:
- (i) FY26 domestic SSS guidance cut below 3% floor — **NOT-TRIPPED.** Q3 domestic SSS +4.1% constant currency / +5.5% reported = comfortably above 3% floor with multi-quarter acceleration documented. **No 8-K guide cut.**
- (ii) Structural US auto-parts demand disruption (major EV-replacement program reducing ICE maintenance demand) — **NOT-TRIPPED.**
- (iii) Sub-pattern 4 escalation: international-weakness-to-domestic-contagion confirmation in quarterly guidance — **NOT-TRIPPED** (Q3 itself showed Mexico SSS +1.6% constant-currency vs domestic +4.1% — international IS weaker but the **contagion direction is the wrong sign for thesis-invalidation: domestic accelerated while international softened**, the opposite of cross-contamination).
None tripped. **But heightened watch is warranted on:**
- **(a) Sub-pattern 4a adjacency (AEO precedent):** if a 2nd-3rd PT cut firm matches Citi/Jefferies and a 4th-5th cut takes a target **to-or-below spot ($2,935)**, the sub-pattern flips toward AEO-style information-driven repricing. Current state: PT-cluster still above spot by 26–37%; thesis intact.
- **(b) Implicit FY26 framework integrity:** AZO Q4 (fiscal year ending late August) results land ~late September — well outside the 60-day window. A pre-announcement / 8-K guide cut during the window would be criterion (i); none present.

**6. Time to thesis resolution.** **54 calendar days to time-exit 2026-07-24.** Convergence +9.0% above spot. Time-exit event live (`c198nmdf8quptsc4kvt7pvoq58`, Fri 2026-07-24 07:15 MT). No print-in-window catalyst. The Mexico-peso 13% YoY tailwind cited in Q3 transcript ($74M sales / $20M EBIT / $0.83 EPS benefit) provides a structural margin support; reversal would be FX-driven, not criterion-event-driven.

**Recommendation: HOLD — WATCH ELEVATED.** No criterion (i)/(ii)/(iii) tripped at present. **D1/D2 daily-watch tightening:** flag any 3rd-firm PT cut on AZO this week; flag any AZO 8-K; flag any analyst-action that takes a PT to-or-below $2,935 (information-pricing inflection). If the AEO 5/29 sub-pattern 4a pattern fires (≥3-firm cuts re-rating to information-driven equilibrium), W4 next cycle should re-adjudicate criterion (iii); current week does not trigger that adjudication. KL #12 6/3 review owns the AZO × TJX × BURL Consumer-Disc cluster correlation read.

---

### B-6: Burlington Stores (OPEN PROVISIONAL — convergence target EXCEEDED on Day-1; fill-capture session owns exit staging)

**1. Current thesis status.** Post-event mispricing long entered Fri 2026-05-29 at ≈$300.60 (inferred; PROVISIONAL — IBKR screenshot reconciliation owed via event `re0irs9o1rcrg0c98rh9ranih0`). The Decision_Log GO entry was **never written** (partial-commit failure flagged in Decision_Log 2026-05-29 BKE entry + 2026-05-30 D3 Flag 1). Recoverable order parameters: convergence target **$313.71** (immutable; matches the BURL TJX 5/23 / under-reaction-family parameter set); staged Limit BUY $303.00 DAY; 2% B-NAV sizing → ~$37.7 principal → ~0.1255 shares. **Day-1 result:** BURL Q1 FY26 print BMO 5/29 beat-and-raise; the stock opened $300.60 (below the $303 buy-limit → fill at open ≈ $300.60), traded a 5/29 OHLC of $300.60 / $324.69 / $297.35 / **$323.83 close**. **The convergence target $313.71 was exceeded at the 5/29 close ($323.83) on the day of entry.** Per Strategy.md B exit rules ("convergence target reached"), the position is **convergence-exit-due**.

**2. Competitive landscape.** Same off-price cohort as TJX (Apparel Retail / off-price). Print-day peer action: LULU −0.69%, ROST −1.07%, TJX −1.87%, GAP +1.2%, BOOT −0.79%, BKE −9.13% (substantive Q1 fade, see Decision_Log 2026-05-29 BKE NO-GO + 2026-05-30 BKE substantive re-evaluation). Scanner data per StockTitan: "no broad sector momentum, suggesting this earnings beat-and-raise is primarily stock-specific rather than part of a coordinated off-price rally." The BURL move is the cleanest sub-pattern-1 / sub-pattern-3 candidate of the off-price cohort this week.

**3. Fundamental developments.** Q1 FY26 print: revenue $2.86B (+14% YoY); EPS $2.10 (vs ~$1.69 cons; +24% YoY); **comps +6%** (well above guidance, raised from prior-year +5%); operating margin +20 bps (beat guide by 100 bps); **FY26 EPS guide raised to $11.45–$11.80** (consensus had $11.23); FY26 revenue guide raised to $12.6–$12.8B; **Q2 FY26 guide $2.05–$2.20 EPS / +10–12% sales / +30-60 bps op margin** (Q2 outlook 19–28% EPS growth; "May month-to-date tracking at high end of comp guidance range"); 14th consecutive quarter of double-digit EPS growth; $747M cash; $111M convertible-note repurchase. **Bank of America (5/29): Buy maintained; PT $367 → $375 (+2.2%, modest raise).** Yahoo "Latest Rating" confirms; not a sub-pattern-1 aggressive-multi-firm wave (single +2.2% raise).

**4. Sector / macro context.** Off-price tailwind from G-shaped consumer divergence (Daily.md 5/30); BURL's beat-and-raise corroborates the off-price-strength sub-thesis (parallel to TJX). No macro headwind specific to BURL this week.

**5. Thesis-invalidation signals.** Per recoverable staging parameters (the full Decision_Log GO entry is missing — actual invalidation criteria are PENDING reconstruction at fill-capture). Treating sub-pattern-1 (B template) by default:
- (i) FY26 framework reset / guide-cut equivalent — **NOT-TRIPPED** (FY26 guide was just RAISED).
- (ii) Pre-announcement / demand reversal — **NOT-TRIPPED.**
- (iii) Sub-pattern-1 escalation (aggressive PT-raise wave) — **NOT-TRIPPED** (only single BofA modest +2.2% raise so far).
**The relevant exit trigger is criterion-3 "convergence target reached," not an invalidation criterion.**

**6. Time to thesis resolution.** **Convergence already reached at Day-1 close.** Time-based exit 2026-07-28 (~58 days) is the backstop event (`91sgtm5com859vib9gu1a0brfs`); fill-capture session is the canonical resolution path. **The position is operationally exit-due now; the gating constraint is the IBKR-screenshot reconciliation, not the thesis.**

**Recommendation: CLOSE ON THESIS COMPLETION (CONVERGENCE) — STAGING OWED TO FILL-CAPTURE SESSION.** Cited rule: Strategy.md B exit — "Convergence target reached" ($313.71; 5/29 close $323.83 = first close above target on day-of-entry). **W4 should NOT stage** the exit directly — operator IBKR screenshot via the fill-capture event is the prerequisite. **W4 chat-output flag:** surface IMMEDIATE-ACTION for operator to paste IBKR Positions + Trades screenshot into a fresh session using the prompt in event `re0irs9o1rcrg0c98rh9ranih0` (or direct the next D2/fresh session to reconstruct per Portfolio_Ledger 2026-05-29 + Decision_Log 2026-05-30 D3 Flag 1). Fill-capture session is responsible for: (a) confirming exact fill/qty/commission, (b) writing the missing Decision_Log GO thesis entry (reconstructed from D3-preserved params + 5/28 BURL thesis-construction session context), (c) finalizing Portfolio_Ledger BURL OPEN section, (d) **staging the convergence exit SELL — a market sell at the Mon 6/1 open is the fastest cleanest path given the price is already through target and the BURL Q2 guide-raise day-2 trajectory could reverse**, (e) creating execute-order + fill-capture calendar events for the exit.

---

## Cross-Position & Macro Context (W22 close / 2026-05-29)

- **Tape:** Fri 5/29 three-way fresh record close (SPX 7,580.06 / Nasdaq 26,972.62 / Dow 51,032.46 first 51k close + 9th straight S&P weekly gain; Dow's all-time high; "best month since 2001" Nasdaq +8% May / computer-hardware-peripherals group +69% May per IBD). VIX 15.32 = multi-week low; SPY Trend = NEUTRAL or potentially testing UP cross (M1 6/1 owns the call). Brent ~$110 (Iran slow-fade; Polymarket Hormuz-normal-by-7/31 60%); 10Y UST ~4.45–4.48%. None of these moves alters a B criterion.
- **B router:** ACTIVATE confirmed; M1 6/1 fires Monday with re-derivation including the W22 software / AI-infrastructure / AI-industry-signal cluster (Anthropic $965B raise; SpaceX $1.8T IPO; Blue Origin failure; Goldman 8,000 S&P PT) and dissenting bubble-framing (Smead, Northlight).
- **Portfolio correlation (KL #12):** book is six longs spanning five GICS sectors (Health Care Facilities; Communications Equipment; Industrial Machinery; Apparel Retail × 2 — TJX + BURL; Automotive Retail — AZO). **TJX × BURL is the most likely correlation flag** (same Apparel Retail sub-industry; same off-price competitive frame; same Day-1+ trajectory window). KL #12 metric (d) first computation Wed 2026-06-03 (event `k9vtudr7d40ukto3vfhutcdbls`); rev 35 makes this a monitoring flag (> 0.5 average pairwise daily-return correlation) rather than an entry block.
- **Scheduled catalysts inside open-position windows:**
  - **HCA:** no scheduled HCA-specific catalyst inside the 27-day window; Medicaid policy is slow-drip macro (already-priced 2025 reconciliation law; deepest cuts October 2027+).
  - **ZBRA:** mid-window pulse Tue 2026-06-09 (event live).
  - **BRC:** no fiscal Q4 print inside window (BRC FY ends 7/31; Q4 print ~September); Honeywell PSS regulatory milestone may surface during H2.
  - **TJX:** Q2 FY27 print ~mid-August (outside window); off-price-peer prints (BURL already in book; ROST recently printed) are sub-pattern monitoring inputs.
  - **AZO:** Q4 FY26 print ~late September (outside window). FOMC 2026-06-16/17 inside window (general consumer-discretionary read-through; not AZO-specific criterion).
  - **BURL:** convergence reached on Day-1; gating is fill-capture reconciliation.
- **B experiment tally context:** B tally standing ~6 GO + ~55-56 NO-GO post-rev-35 AEO/BKE re-evaluation (W5 reconciliation drift; not material for W3). B-short string ~40 post-AEO substantive NO-GO. Conviction-calibration ladder unchanged.
- **Operating_Protocols §10 rev 35 reminder:** Do NOT express B concurrent-position counts as X/N — rev 35 removes all B holdings-count caps. The 6 open B longs / 3 Consumer-Disc concurrent longs are absolute counts (informational), not against any ceiling.

---

## Summary Recommendation Table

| Position | Status | To convergence | Recommendation | Cited criterion / key watch |
|----------|--------|-----------------|----------------|------------------------------|
| HCA  | OPEN | +17.0% (adverse, $378.54) | **HOLD — time-expiry watch ELEVATED** | Criteria (i)–(iv) NOT-TRIPPED; no B price-stop. 27 days to 2026-06-27 time-exit; structurally expected lower-conviction tail. Catalyst paths: HCA 8-K reaffirmation / Medicaid headline → criterion (i) check. No W4 action — 6/26 time-exit event handles staging at expiry. |
| ZBRA | OPEN | +8.36% ($264.00) | **HOLD** | Criteria (i)–(iv) NOT-TRIPPED; thesis intact; sub-pattern-1 split-cluster confirmed; mid-window pulse Tue 6/9 owns structured re-look. |
| BRC  | OPEN | +3.26% ($88.80) | **HOLD — APPROACHING TARGET** | Criteria (i)–(iii) NOT-TRIPPED; intraday print above $88.80 on 5/26 (closed below). D2 daily-watch: first close ≥ $88.80 → stage convergence SELL per Strategy.md. D2 to verify 5/29 close at next session. |
| TJX  | OPEN | +6.30% ($164.50) | **HOLD** | Criteria (i)–(iii) NOT-TRIPPED; sub-pattern-1 cleanly clears (max raise Truist +8.6% « 20% threshold); off-price-tailwind cross-section corroborates (ROST raise; BURL beat). |
| AZO  | OPEN | +9.02% ($3,200) | **HOLD — WATCH ELEVATED** | Criteria (i)–(iii) NOT-TRIPPED; Citi PT $4,300 → $3,700 + Jefferies → $4,000 are first PT-cut signals but cluster remains ~+26-37% above spot (not information-driven repricing). D1/D2 to flag any 3rd-firm PT cut, any cut to-or-below spot $2,935, or any AZO 8-K. KL #12 owns Consumer-Disc cluster correlation. |
| BURL | OPEN (PROV.) | **target exceeded (+3.2% above $313.71)** | **CLOSE ON THESIS COMPLETION — STAGING OWED TO FILL-CAPTURE SESSION** | Strategy.md "convergence target reached" ($313.71; 5/29 close $323.83). W4 surfaces IMMEDIATE-ACTION flag; operator IBKR screenshot via fill-capture event `re0irs9o1rcrg0c98rh9ranih0` is prerequisite for exact-size SELL staging. Recommended exit mode: market sell at Mon 6/1 open. |

**IMMEDIATE-ACTION:** **BURL convergence exit DUE — fill-capture screenshot owed; operator action required.** All other positions HOLD.
